Replies to post #167845 on Biotech Values

[DewDiligence]

You are increasing the chance of a serious bleed putting someone on a clopidogrel [Plavix].

There’s always a tradeoff between thrombosis and bleeding with any anticoagulant or antiplatelet drug. However, given what we now know about Iclusig’s side effects, I would expect the addition of a antiplatelet drug to provide a net benefit on the whole.

That increase in 11% in thrombosis might be a certain subpopulation if you argue the bleeding risk is neutralized.

I do not understand this sentence—please clarify.

[cooldrinkh2o]

Inclusig will likely be second line if pt fails tasigna


The DC rates for the ABLs are close to 20% and the AE profiles are different enough that I think Iclusig will still get use. The uptake curve, however, will likely become more shallow - closer to the original nilotinib uptake curve.